Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kamada ( (IL:KMDA) ) just unveiled an update.
Kamada Ltd., a global biopharmaceutical company focused on specialty plasma-derived therapies for rare and serious conditions, operates a portfolio of FDA-approved products alongside third-party drug distribution in Israel and the MENA region. The company is also expanding its U.S. plasma collection network and pursuing business development and M&A to drive long-term profitable growth.
On May 6, 2026, Kamada announced it will report financial results for the first quarter ended March 31, 2026, before the U.S. market opens on May 13, 2026. Management will host a same-day conference call for investors, signaling continued engagement with the capital markets and offering stakeholders an opportunity to assess the company’s operating progress and execution of its growth strategy.
The most recent analyst rating on (IL:KMDA) stock is a Buy with a ILs13.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.
More about Kamada
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies and treatments for rare and serious conditions. Its portfolio includes six FDA-approved plasma-derived products, additional hyper-immune and anti-snake venom therapies, and distributed pharmaceuticals in Israel and the MENA region, supported by three FDA-approved plasma collection centers in Texas and a growth strategy that combines organic expansion, in-licensing, and M&A.
Average Trading Volume: 62,845
Technical Sentiment Signal: Buy
Current Market Cap: ILs1.41B
For detailed information about KMDA stock, go to TipRanks’ Stock Analysis page.